December 18, 2025 6:18pm

Thursday, CAPR yells as the roller-coaster crests-up, now waiting for the downslide groan! Opened -$0.04, flipped +$0.66, mid-day to -$0.02 closing at +$0.04.

Doubts still abound re: regulatory fragility and marginal HOPE-3 results and valuation concerns remain a key hang-up!

CAPR remains a structurally challenged, chronically unprofitable company whose valuation is disconnected from fundamentals.

Despite years of promoting Deramiocel (CAP-1002) as a potential treatment for Duchenne muscular dystrophy (DMD); CAPR has yet to generate any meaningful/partnering revenue only losses, relying on repeated capital raises and marketing narratives to sustain operations.

Statistical significance was achieved only by the thinnest margins (PUL: p=0.029; LVEF: p=0.041), highlighting the fragility of the data, and efficacy claims are largely optical, derived from percentage slowing of progression in a late-stage, non-ambulatory patient population where functional measurements are inherently noisy.

 

Safety reporting remains limited, and pivotal cardiac endpoints are based on a thin sample size, providing support but not decisiveness.

As a result, the FDA’s approval probability remains uncertain, with HOPE-3 improving sentiment but not fundamentally de-risking the asset.

While headlines may drive short-term stock pops, the underlying business model, dependence on speculative clinical outcomes, and marginal trial data suggest prolonged regulatory friction and a likely eventual reset closer to cash value, reinforcing the bearish thesis for investors seeking evidence-based returns.  <Insider Monkey>

 

Wednesday, 12/17 … Maintaining MY opinion and conviction; I STILL believe CAPR is Humpty-Dumpty

CAPR finally had a webinar to explain its recent P3 results, after dramatic equity flip-flops and yesterday’s pricing drops!

Capricor Therapeutics (CAPR) opened up +$0.64 on Wednesday was down -$0.01, at 3 pm and closed at +$0.13 after Tuesday’s -$0.53 while diving <-$4.36 in 6 sessions> a little late to have had a webinar, after announcing their P3 pr, instead of “clueing-in” bankers before INVESTORS! SEC anyone …!!

If investors had been reading the daily, you would have known their limitations!

 

 

Right again!

 

I would also ask if the SEC should investigate the post news run-up and the sudden offering financing pricing … 12/2 pricing = $6.36, 12/3 P3 results PR, 12/4 offering price of $25.00 to today’s … $26.01 so far?

  • Desperate times influenced a “sudden” Wednesday webinar!

CAPR should have had this webinar EARLIER, after announcing their P3 pr, instead of “clueing-in” bankers before INVESTORS! SEC anyone …!!

  • I believe CAPR got some “friendly” brokers to PROP and BUY; yet how long this HIGH last???

CAPR STILL has MANY remaining risks are tied to HOPE-3 and “upcoming” priority review?

  • Make your own decision to CUT-BACK as regulatory moving pieces will shape the investment narrative

Investors may wish to stay informed to better track and interpret future shifts in CAPR's soon to be evolving story – can you afford to wait and possibly take a hit out-of-the-blue.

 

HEDGE your RISK, it will travel down … waiting for the FDA which has had past and present questions!